Oral Answers to Questions

James Gray Excerpts

Tuesday 2nd November 2010 Commons Chamber

[Anne Milton]

May I point out to the hon. Lady that, in fact, GPs are often very aware of the services that are needed? The neuromuscular team attached to the SWSCG has worked with the South West Muscle Group on the development of a provider register for hydrotherapy services, for example. Such things are best decided by GPs, who know exactly what people need, what treatment is needed and what care services are needed to ensure the best possible outcomes and the best possible quality of life.

[Mr James Gray (North Wiltshire) (Con)]

The national service framework for long-term conditions such as multiple sclerosis, in which I am very interested, was much praised at the time it was launched. Does the Minister feel that it was properly funded and that it has been run properly since? Has it lived up to the expectations that we all had of it three or four years ago when it was launched?

[Mr Speaker]

With particular reference to the care provided in Bristol.

--- Later in debate ---

[Mr Lansley]

The hon. Lady’s constituents expect the truth, which is that we are providing increased resources for the NHS in real terms, taking it from £104 billion to £114 billion. That is completely contrary to what we were advised to do by the Labour party, which said that we should cut the NHS budget. We did not do that; we increased it.

[Mr James Gray (North Wiltshire) (Con)]

T2. The all-party group on multiple sclerosis held an all-day seminar last week on the subject of drug pricing, during which it broadly welcomed the end of the risk-sharing scheme and looked forward to value-based pricing, which will be introduced shortly. That welcome is subject to two important conditions: first, that NICE clinical guidelines should be updated and continued; and secondly, that the NICE risk appraisal should be abandoned. Does the Secretary of State agree with me on those two conditions?

[Mr Lansley]

Yes; my hon. Friend is absolutely right. As we implement our plans for the value-based pricing of medicines from 2014, NICE’s role will change. It will focus on advising how best to use treatments and to develop quality standards for the NHS, rather than recommending whether patients should be able to access particular drugs. We want patients to have access to the medicines that their clinicians believe are best for them.